Measuring the return from pharmaceutical innovation
Key takeaways In 2025, R&D productivity across the top 20 biopharma companies showed modest improvement, with projected IRR rising to 7.0%; yet, this gain is heavily concentrated in a narrow set of GLP-1/GIP assets. Beneath the headline, underlying productivity remains challenged, raising important questions about the sustainability of current innovation models. We’ll discuss: Practical approaches...

